Centogene and evotec discover promising new molecule to treat gaucher disease

Cambridge, mass. and rostock, germany and berlin, may 14, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with evotec se (frankfurt stock exchange: evt, mdax/tecdax, isin: de0005664809; nasdaq: evo). the new molecule has the potential to treat patients with type 2 and type 3 gaucher disease, otherwise known as neuronopathic gaucher disease. the discovery has been the result of the collaborative work under the existing drug discovery partnership which has been in place since 2020.
CNTG Ratings Summary
CNTG Quant Ranking